PureTech Regulatory News (PRTC)

PureTech Information

Buy PRTC Shares
Add PRTC to Watchlist
Add PRTC to Alert

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 228.00

Bid: 226.00

Ask: 228.50

Change: 1.00 (0.44%)

Spread: 2.50 (1.106%)

Open: 227.00

High: 229.00

Low: 225.00

Prev. Close: 227.00

Last checked at -

Transaction in Own Shares

6 Jun 2023 07:00

RNS Number : 7179B

PureTech Health PLC

06 June 2023

6 June 2023

PureTech Health plc

Transaction in Own Shares

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

Date of purchase:	5 June 2023

Number of ordinary shares purchased:	17,052

Highest price paid per share:	234.50p

Lowest price paid per share:	232.50p

Volume weighted average price paid per share:	234.45p

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 11,963,789 ordinary shares in treasury and has 277,504,370 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 277,504,370 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both US FDA clearance and European marketing authorization and a third (KarXT) that is expected to be filed soon for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

Transaction Date	Transaction Time	Volume	Price (GBp)	Platform	Transaction Reference Number
05/06/2023	16:07:20	38	234.5	CHIX	00355359348TRLO1.1.1
05/06/2023	16:07:20	42	234.5	CHIX	00355359346TRLO1.1.1
05/06/2023	16:07:20	56	234.5	CHIX	00355359347TRLO1.1.1
05/06/2023	16:07:20	51	234.5	CHIX	00355359344TRLO1.1.1
05/06/2023	16:07:20	154	234.5	CHIX	00355359345TRLO1.1.1
05/06/2023	16:06:20	17	234.5	TRQX	00355358773TRLO1.1.1
05/06/2023	16:06:20	14	234.5	TRQX	00355358772TRLO1.1.1
05/06/2023	16:06:20	536	234.5	TRQX	00355358771TRLO1.1.1
05/06/2023	16:06:20	13	234.5	TRQX	00355358769TRLO1.1.1
05/06/2023	16:06:20	13	234.5	TRQX	00355358770TRLO1.1.1
05/06/2023	16:06:20	13	234.5	TRQX	00355358767TRLO1.1.1
05/06/2023	16:06:20	13	234.5	TRQX	00355358768TRLO1.1.1
05/06/2023	16:06:20	13	234.5	TRQX	00355358765TRLO1.1.1
05/06/2023	16:06:20	13	234.5	TRQX	00355358766TRLO1.1.1
05/06/2023	16:06:20	16	234.5	TRQX	00355358763TRLO1.1.1
05/06/2023	16:06:20	17	234.5	TRQX	00355358762TRLO1.1.1
05/06/2023	16:06:20	15	234.5	TRQX	00355358764TRLO1.1.1
05/06/2023	16:06:20	19	234.5	TRQX	00355358761TRLO1.1.1
05/06/2023	16:06:20	10	234.5	TRQX	00355358760TRLO1.1.1
05/06/2023	16:06:20	11	234.5	TRQX	00355358758TRLO1.1.1
05/06/2023	16:06:20	12	234.5	TRQX	00355358759TRLO1.1.1
05/06/2023	16:06:20	13	234.5	TRQX	00355358757TRLO1.1.1
05/06/2023	16:06:20	13	234.5	TRQX	00355358755TRLO1.1.1
05/06/2023	16:06:20	13	234.5	TRQX	00355358756TRLO1.1.1
05/06/2023	16:06:20	11	234.5	TRQX	00355358754TRLO1.1.1
05/06/2023	16:06:20	12	234.5	TRQX	00355358753TRLO1.1.1
05/06/2023	16:06:20	16	234.5	TRQX	00355358752TRLO1.1.1
05/06/2023	16:06:20	52	234.5	TRQX	00355358751TRLO1.1.1
05/06/2023	16:06:20	190	234.5	XLON	00355358750TRLO1.1.1
05/06/2023	16:06:20	181	234.5	XLON	00355358749TRLO1.1.1
05/06/2023	16:06:20	7	234.5	TRQX	00355358748TRLO1.1.1
05/06/2023	16:06:20	13	234.5	TRQX	00355358747TRLO1.1.1
05/06/2023	16:06:20	611	234.5	XLON	00355358746TRLO1.1.1
05/06/2023	16:06:20	232	234.5	XLON	00355358745TRLO1.1.1
05/06/2023	16:06:19	9	234.5	AQXE	00355358740TRLO1.1.1
05/06/2023	16:06:19	24	234.5	AQXE	00355358739TRLO1.1.1
05/06/2023	16:06:19	101	234.5	AQXE	00355358738TRLO1.1.1
05/06/2023	16:06:19	21	234.5	AQXE	00355358737TRLO1.1.1
05/06/2023	16:06:19	23	234.5	AQXE	00355358736TRLO1.1.1
05/06/2023	16:06:19	66	234.5	AQXE	00355358735TRLO1.1.1
05/06/2023	16:06:19	23	234.5	AQXE	00355358734TRLO1.1.1
05/06/2023	16:06:19	23	234.5	AQXE	00355358733TRLO1.1.1
05/06/2023	16:06:19	29	234.5	AQXE	00355358732TRLO1.1.1
05/06/2023	16:06:19	43	234.5	AQXE	00355358730TRLO1.1.1
05/06/2023	16:06:19	22	234.5	AQXE	00355358731TRLO1.1.1
05/06/2023	16:06:19	30	234.5	AQXE	00355358729TRLO1.1.1
05/06/2023	16:06:19	24	234.5	AQXE	00355358728TRLO1.1.1
05/06/2023	16:06:19	24	234.5	AQXE	00355358727TRLO1.1.1
05/06/2023	16:06:19	16	234.5	AQXE	00355358726TRLO1.1.1
05/06/2023	16:06:19	23	234.5	AQXE	00355358724TRLO1.1.1
05/06/2023	16:06:19	30	234.5	AQXE	00355358723TRLO1.1.1
05/06/2023	16:06:19	22	234.5	AQXE	00355358725TRLO1.1.1
05/06/2023	16:06:19	22	234.5	AQXE	00355358722TRLO1.1.1
05/06/2023	16:06:19	28	234.5	AQXE	00355358721TRLO1.1.1
05/06/2023	16:06:19	22	234.5	AQXE	00355358720TRLO1.1.1
05/06/2023	16:06:19	24	234.5	AQXE	00355358719TRLO1.1.1
05/06/2023	16:06:19	22	234.5	AQXE	00355358718TRLO1.1.1
05/06/2023	15:27:29	10	234.5	XLON	00355341115TRLO1.1.1
05/06/2023	15:26:34	500	234.5	XLON	00355340750TRLO1.1.1
05/06/2023	15:26:34	107	234.5	XLON	00355340749TRLO1.1.1
05/06/2023	15:26:34	145	234.5	XLON	00355340748TRLO1.1.1
05/06/2023	15:26:34	52	234.5	BATE	00355340746TRLO1.1.1
05/06/2023	15:26:34	60	234.5	BATE	00355340747TRLO1.1.1
05/06/2023	15:26:34	66	234.5	BATE	00355340745TRLO1.1.1
05/06/2023	15:26:34	69	234.5	BATE	00355340744TRLO1.1.1
05/06/2023	15:26:34	22	234.5	BATE	00355340743TRLO1.1.1
05/06/2023	15:26:34	3	234.5	CHIX	00355340742TRLO1.1.1
05/06/2023	15:26:34	45	234.5	CHIX	00355340741TRLO1.1.1
05/06/2023	15:26:34	30	234.5	CHIX	00355340740TRLO1.1.1
05/06/2023	15:26:34	14	234.5	CHIX	00355340739TRLO1.1.1
05/06/2023	15:26:34	52	234.5	CHIX	00355340738TRLO1.1.1
05/06/2023	15:26:34	47	234.5	CHIX	00355340737TRLO1.1.1
05/06/2023	15:26:34	47	234.5	CHIX	00355340736TRLO1.1.1
05/06/2023	15:26:34	36	234.5	CHIX	00355340735TRLO1.1.1
05/06/2023	15:26:34	179	234.5	XLON	00355340734TRLO1.1.1
05/06/2023	15:26:34	51	234.5	BATE	00355340731TRLO1.1.1
05/06/2023	15:26:34	306	234.5	XLON	00355340733TRLO1.1.1
05/06/2023	15:26:34	41	234.5	BATE	00355340732TRLO1.1.1
05/06/2023	15:26:34	43	234.5	BATE	00355340730TRLO1.1.1
05/06/2023	15:26:34	61	234.5	BATE	00355340728TRLO1.1.1
05/06/2023	15:26:34	62	234.5	BATE	00355340729TRLO1.1.1
05/06/2023	15:26:34	272	234.5	BATE	00355340727TRLO1.1.1
05/06/2023	15:26:34	50	234.5	BATE	00355340725TRLO1.1.1
05/06/2023	15:26:34	65	234.5	BATE	00355340726TRLO1.1.1
05/06/2023	15:26:34	58	234.5	BATE	00355340724TRLO1.1.1
05/06/2023	15:26:34	61	234.5	BATE	00355340722TRLO1.1.1
05/06/2023	15:26:34	45	234.5	BATE	00355340723TRLO1.1.1
05/06/2023	15:26:34	104	234.5	BATE	00355340721TRLO1.1.1
05/06/2023	15:26:34	168	234.5	BATE	00355340720TRLO1.1.1
05/06/2023	15:26:34	619	234.5	BATE	00355340719TRLO1.1.1
05/06/2023	15:26:34	190	234.5	XLON	00355340717TRLO1.1.1
05/06/2023	15:26:34	19	234.5	XLON	00355340716TRLO1.1.1
05/06/2023	15:26:34	44	234.5	CHIX	00355340715TRLO1.1.1
05/06/2023	15:26:34	42	234.5	CHIX	00355340714TRLO1.1.1
05/06/2023	15:26:34	45	234.5	CHIX	00355340713TRLO1.1.1
05/06/2023	15:26:34	50	234.5	CHIX	00355340712TRLO1.1.1
05/06/2023	15:26:34	45	234.5	CHIX	00355340711TRLO1.1.1
05/06/2023	15:26:34	39	234.5	CHIX	00355340710TRLO1.1.1
05/06/2023	15:26:34	41	234.5	CHIX	00355340709TRLO1.1.1
05/06/2023	15:26:34	47	234.5	CHIX	00355340708TRLO1.1.1
05/06/2023	15:26:34	41	234.5	CHIX	00355340707TRLO1.1.1
05/06/2023	15:26:34	181	234.5	CHIX	00355340706TRLO1.1.1
05/06/2023	15:26:34	108	234.5	CHIX	00355340705TRLO1.1.1
05/06/2023	15:26:34	38	234.5	CHIX	00355340704TRLO1.1.1
05/06/2023	15:26:34	428	234.5	CHIX	00355340702TRLO1.1.1
05/06/2023	15:26:34	52	234.5	CHIX	00355340703TRLO1.1.1
05/06/2023	15:26:34	37	234.5	CHIX	00355340701TRLO1.1.1
05/06/2023	15:26:34	40	234.5	CHIX	00355340700TRLO1.1.1
05/06/2023	15:26:34	236	234.5	XLON	00355340699TRLO1.1.1
05/06/2023	15:26:34	472	234.5	XLON	00355340698TRLO1.1.1
05/06/2023	15:26:34	862	234.5	XLON	00355340697TRLO1.1.1
05/06/2023	15:26:34	2346	234.5	XLON	00355340696TRLO1.1.1
05/06/2023	15:26:34	82	234.5	BATE	00355340695TRLO1.1.1
05/06/2023	15:26:34	52	234.5	BATE	00355340694TRLO1.1.1
05/06/2023	15:26:34	57	234.5	BATE	00355340693TRLO1.1.1
05/06/2023	15:26:34	94	234.5	BATE	00355340692TRLO1.1.1
05/06/2023	15:26:34	90	234.5	BATE	00355340691TRLO1.1.1
05/06/2023	15:26:34	6	234.5	TRQX	00355340690TRLO1.1.1
05/06/2023	15:26:34	11	234.5	TRQX	00355340689TRLO1.1.1
05/06/2023	15:26:34	3	234.5	TRQX	00355340688TRLO1.1.1
05/06/2023	15:26:34	194	234.5	XLON	00355340686TRLO1.1.1
05/06/2023	15:26:34	11	234.5	TRQX	00355340687TRLO1.1.1
05/06/2023	15:26:34	228	234.5	XLON	00355340684TRLO1.1.1
05/06/2023	15:26:34	244	234.5	XLON	00355340685TRLO1.1.1
05/06/2023	15:26:34	1033	234.5	XLON	00355340683TRLO1.1.1
05/06/2023	15:26:34	332	234.5	XLON	00355340682TRLO1.1.1
05/06/2023	15:26:34	8	234.5	TRQX	00355340681TRLO1.1.1
05/06/2023	15:26:34	14	234.5	TRQX	00355340680TRLO1.1.1
05/06/2023	15:26:34	18	234.5	TRQX	00355340678TRLO1.1.1
05/06/2023	15:26:34	18	234.5	TRQX	00355340679TRLO1.1.1
05/06/2023	15:26:34	12	234.5	TRQX	00355340677TRLO1.1.1
05/06/2023	15:26:34	12	234.5	TRQX	00355340676TRLO1.1.1
05/06/2023	15:26:34	150	234.5	XLON	00355340675TRLO1.1.1
05/06/2023	15:26:34	328	234.5	XLON	00355340674TRLO1.1.1
05/06/2023	15:26:34	271	234.5	XLON	00355340673TRLO1.1.1
05/06/2023	15:26:34	16	234.5	XLON	00355340671TRLO1.1.1
05/06/2023	15:26:34	206	234.5	XLON	00355340672TRLO1.1.1
05/06/2023	15:26:34	157	234.5	XLON	00355340670TRLO1.1.1
05/06/2023	15:26:34	254	234.5	XLON	00355340669TRLO1.1.1
05/06/2023	15:26:34	10	234.5	TRQX	00355340668TRLO1.1.1
05/06/2023	15:26:34	13	234.5	TRQX	00355340667TRLO1.1.1
05/06/2023	15:26:34	13	234.5	TRQX	00355340666TRLO1.1.1
05/06/2023	15:26:34	208	234.5	XLON	00355340664TRLO1.1.1
05/06/2023	15:26:34	372	234.5	XLON	00355340665TRLO1.1.1
05/06/2023	08:14:25	21	233	AQXE	00355211754TRLO1.1.1
05/06/2023	08:09:23	47	232.5	CHIX	00355210856TRLO1.1.1
05/06/2023	08:09:10	224	233	XLON	00355210839TRLO1.1.1
05/06/2023	08:07:16	21	233	AQXE	00355210637TRLO1.1.1
05/06/2023	08:05:00	208	233	XLON	00355210439TRLO1.1.1

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

POSFLFEDRLIEIIV

Date		Source	Headline
18th Nov 2021	12:10 pm	RNS	PRTC's Gelesis Receives $30M Plenity Order from Ro
16th Nov 2021	12:00 pm	RNS	PRTC Publishes Previous LYT-100 MAD Study Results
15th Nov 2021	12:00 pm	RNS	PRTC Presents at Two Upcoming Investor Conferences
12th Nov 2021	12:00 pm	RNS	PRTC Presents Immunooncology Ph 1/2 Trial at SITC
11th Nov 2021	12:00 pm	RNS	FDA Grants PRTC's LYT-200 Orphan Drug Designation
10th Nov 2021	7:00 am	RNS	PRTC Receives $100M from Founded Entity Shares
9th Nov 2021	12:34 pm	RNS	KRTX and Zai Lab to Develop KarXT in Greater China
9th Nov 2021	7:00 am	RNS	PRTC Presents at Jefferies Healthcare Conference
1st Nov 2021	10:20 am	RNS	New Research in Journal Nature on Gelesis Tech
1st Nov 2021	7:00 am	RNS	Total Voting Rights
22nd Oct 2021	6:00 pm	RNS	Holdings in Company - TR-1 Correction Announcement
20th Oct 2021	4:35 pm	RNS	Price Monitoring Extension
14th Oct 2021	12:01 pm	RNS	PRTC's Vedanta Appoints Chief Legal Officer
12th Oct 2021	7:00 am	RNS	Additional Listing
5th Oct 2021	1:01 pm	RNS	Vedanta Positive Phase 2 Data in C. Diff Infection
5th Oct 2021	1:00 pm	RNS	PRTC's Sonde Launches Mental Health Monitor
29th Sep 2021	1:01 pm	RNS	Akili/Shionogi Report Positive Ph2 Data in Japan
20th Sep 2021	4:02 pm	RNS	New PureTech Research Published In Nature Journal
14th Sep 2021	12:00 pm	RNS	PRTC to Present at Oppenheimer Healthcare Summit
1st Sep 2021	7:00 am	RNS	Total Voting Rights
24th Aug 2021	7:00 am	RNS	Half-year Report
23rd Aug 2021	12:00 pm	RNS	PRTC Presents LYT-100 Ph1 PK & Tolerability at ERS
17th Aug 2021	1:03 pm	RNS	Akili Deal Furthers Digital Medicine Leadership
13th Aug 2021	12:00 pm	RNS	PRTC Appoints Industry Veteran & Physician as CMO
11th Aug 2021	12:00 pm	RNS	PRTC Receives $6.5M; Imbrium to Develop LYT-503
3rd Aug 2021	7:00 am	RNS	Notice of Results
2nd Aug 2021	7:00 am	RNS	Total Voting Rights
23rd Jul 2021	7:00 am	RNS	PDMR DEALING - PURCHASE OF SHARES
22nd Jul 2021	1:03 pm	RNS	PRTC’s Akili Releases New Features for EndeavorRx
22nd Jul 2021	7:00 am	RNS	PDMR DEALING - PURCHASE OF SHARES
21st Jul 2021	12:03 pm	RNS	PureTech’s Vedanta Raises $68M Series D Financing
19th Jul 2021	12:02 pm	RNS	PRTC’s Gelesis to Become Public Via Capstar SPAC
9th Jul 2021	12:00 pm	RNS	PRTC’s Vor Announces Collaboration with Janssen
8th Jul 2021	2:05 pm	RNS	PRTC’s Sonde Announces Collaboration With Qualcomm
7th Jul 2021	12:00 pm	RNS	PRTC BeiGene LYT-200 Clinical Trial Agreement
1st Jul 2021	7:00 am	RNS	Total Voting Rights
30th Jun 2021	12:00 pm	RNS	PRTC’s Vedanta Announces New Data from IBD Study
28th Jun 2021	7:00 am	RNS	PDMR DEALING - PURCHASE OF SHARES
24th Jun 2021	7:00 am	RNS	PDMR DEALING - PURCHASE OF SHARES
23rd Jun 2021	1:28 pm	RNS	Karuna Announces KarXT Results in Healthy Elderly
16th Jun 2021	12:00 pm	RNS	PureTech Acquires Alivio and Oral IL-22 Candidate
2nd Jun 2021	7:00 am	RNS	PDMR Notification RSU Vesting
1st Jun 2021	7:00 am	RNS	Total Voting Rights
27th May 2021	6:16 pm	RNS	Result of AGM
27th May 2021	2:50 pm	RNS	PureTech’s Gelesis Presents Plenity Data at AACE
26th May 2021	1:05 pm	RNS	PureTech’s Akili Secures $160M in Financing
25th May 2021	12:00 pm	RNS	PRTC Presents at Jefferies Healthcare Conference
12th May 2021	12:00 pm	RNS	PureTech Forms IPF Clinical Advisory Board
28th Apr 2021	4:08 pm	RNS	New PureTech Research Published in Nature Journal
26th Apr 2021	1:05 pm	RNS	Gelesis Appoints Procter & Gamble Veteran to BOD

Latest Share Chat

PureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transaction in Own Shares

Login to your account

Quickpicks are a member only feature

Login to your account